Kai Li

Prof. Dr. Kai Li

Harbin Institute of Technology, Harbin, Heilongjiang, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Molecular Immunology
Verified
Journal Article
Closed access
JYJie Yang
Jie Yang
LLLin Liu
Lin Liu
MLMengmeng Li
Mengmeng Li
XHXuemei Huang
Xuemei Huang
HYHuanjie Yang
Huanjie Yang
Kai LiKai Li
Kai Li

13 February 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYing Li
Ying Li
HMHuihui Ma
Huihui Ma
YZYongjian Zhang
Yongjian Zhang
THTinghui He
Tinghui He
BLBinyang Li
Binyang Li
MSMing Shi
Ming Shi
Spontaneous clearance of hepatitis B virus (HBV) is frequent in adults (95%) but rare in infants (5%), emphasizing the critical role of age-related hepatic immunocompetence. However, the underlying mechanisms of hepatocyte-specific immunosurveillance and age-dependent HBV clearance remain unclear. Here, we identified PGLYRP2 as a hepatocyte-specific pattern recognition receptor with age-dependent expression, and demonstrated that phase separation of PGLYRP2 was a critical driver of spontaneous HBV clearance in hepatocytes. Mechanistically, PGLYRP2 recognized and potentially eliminated covalently closed circular DNA via phase separation, coordinated by its intrinsically disordered region and HBV DNA-binding domain (PGLYRP2 IDR/209–377 ) in the nucleus. Additionally, PGLYRP2 suppressed HBV capsid assembly by directly interacting with the viral capsid, mediated by its PGRP domain. This interaction promoted the nucleocytoplasmic translocation of PGLYRP2 and subsequent secretion of the PGLYRP2/HBV capsid complex, thereby bolstering the hepatic antiviral response. Pathogenic variants or deletions in PGLYRP2 impaired its ability to inhibit HBV replication, highlighting its essential role in hepatocyte-intrinsic immunity. These findings suggest that targeting the PGLYRP2-mediated host-virus interaction may offer a potential therapeutic strategy for the development of anti-HBV treatments, representing a promising avenue for achieving a functional cure for HBV infection.

13 November 2019 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
QYQingzhu Yang
Qingzhu Yang
YYYao Yao
Yao Yao
Kai LiKai Li
Kai Li
LJLin Jiao
Lin Jiao
JZJiazhen Zhu
Jiazhen Zhu
HYHuanjie Yang
Huanjie Yang
Repurposing already approved drugs as new anticancer agents is a promising strategy considering the advantages such as low costs, low risks and less time-consumption. Disulfiram (DSF), as the first drug for antialcoholism, was approved by the U.S. Food and Drug Administration (FDA) over 60 years ago. Increasing evidence indicates that DSF has great potential for the treatment of various human cancers. Several mechanisms and targets of DSF related to cancer therapy have been proposed, including the inhibition of ubiquitin-proteasome system (UPS), cancer cell stemness and cancer metastasis, and alteration of the intracellular reactive oxygen species (ROS). This article provides a brief review about the history of the use of DSF in humans and its molecular mechanisms and targets of anticancer therapy, describes DSF delivery strategies for cancer treatment, summarizes completed and ongoing cancer clinical trials involving DSF, and offers strategies to better use DSF in cancer therapies.

24 October 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
XZXiushan Zheng
Xiushan Zheng
JDJiaqiang Dong
Jiaqiang Dong
TGTaiqian Gong
Taiqian Gong
ZZZhiyong Zhang
Zhiyong Zhang
YWYing Wang
Ying Wang
MDMingfan Dai
Mingfan Dai

18 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
XZXiangsheng Zhang
Xiangsheng Zhang
LZLiye Zhong
Liye Zhong
ZZZhilin Zou
Zhilin Zou
GLGuosheng Liang
Guosheng Liang
ZTZhenye Tang
Zhenye Tang
XZXiao Zhu
Xiao Zhu
N6-methyladenosine (m6A) is one of the most active modification factors of mRNA, which is closely related to cell proliferation, differentiation, and tumor development. Here, we explored the relationship between the pathogenesis of hematological malignancies and the clinicopathologic parameters. The datasets of hematological malignancies and controls were obtained from the TCGA [AML (n = 200), DLBCL (n = 48)] and GTEx [whole blood (n = 337), blood vascular artery (n = 606)]. We analyzed the m6A factor expression differences in normal tissue and tumor tissue and their correlations, clustered the express obvious clinical tumor subtypes, determined the tumor risk score, established Cox regression model, performed univariate and multivariate analysis on all datasets. We found that the AML patients with high expression of IGF2BP3, ALKBH5, and IGF2BP2 had poor survival, while the DLBCL patients with high expression of METTL14 had poor survival. In addition, “Total” datasets analysis revealed that IGF2BP1, ALKBH5, IGF2BP2, RBM15, METTL3, and ZNF217 were potential oncogenes for hematologic system tumors. Collectively, the expressions of some m6A regulators are closely related to the occurrence and development of hematologic system tumors, and the intervention of specific regulatory factors may lead to a breakthrough in the treatment in the future.

9 December 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
JLJian Liu
Jian Liu
Kai LiKai Li
Kai Li
RWRui Wang
Rui Wang
SCSisi Chen
Sisi Chen
JWJie Wu
Jie Wu
YPYamei Pang
Yamei Pang
Background: Activating transcription factor 2 (ATF2), a member of the activator protein 1 (AP-1) transcription factor family, has been shown to be involved in the pathobiology of numerous cancers. However, the biological role and mechanism of ATF2 in lung adenocarcinoma (LUAD) remains to be elucidated. Methods: The expression of ATF2, NEAT1 and miR-26a-5p in LUAD tissues and cell lines was detected by qRT-PCR and western blotting. The interaction between ATF2, NEAT1, and miR-26a-5p was validated by chromatin immunoprecipitation, luciferase reporter assay and RNA immunoprecipitation. Cell proliferation, invasion and tumorigenesis of LUAD cells were analyzed by using CCK8, transwell invasion assay and xenograft tumor model. Results: We confirmed that ATF2 expression was increased in LUAD tissues compared with normal adjacent lung tissues. Functional experiments showed that ATF2 positively regulated cell proliferation and invasion in LUAD cells. Moreover, we identified that NEAT1 expression was increased in LUAD tissues and positively correlated with ATF2 expression. Mechanistically, ATF2 could bind to the promoter of NEAT1 to promote its transcription. Rescue experiments showed that ATF2 exerted its oncogenic function in LUAD, at least, partly through NEAT1 upregulation. In turn, NEAT1 could positively regulate ATF2 expression and form a positive feedback loop in LUAD cells. Furthermore, we demonstrated that NEAT1 positively regulated ATF2 expression via sponging miR-26a-5p. Conclusion: ATF2 and NEAT1 form a positive feedback loop mediated by miR-26a-5p and coordinately contribute to LUAD progression.